Polymorphic markers of prostate carcinoma tumor antigen -1(PCTA-1)
AssigneeSerono Genetics Institute S.A.
InventorsMarta Blumenfeld, Lydie Bougueleret, Ilya Chumakov
Life of this patent
Estimating the term…
Abstract
The invention concerns the geNo.mic sequence and cDNA sequences of the PCTA-1 gene. The invention also concerns biallelic markers of the PCTA-1 gene and the association established between these markers and prostate cancer. The invention provides means to determine the predisposition of individuals to prostate cancer as well as means for the diagNo.sis of prostate cancer and for the progNo.sis/detection of an eventual treatment response to agents acting against prostate cancer.
Claims41
An isolated, purified or recombinant polynucleotide comprising SEQ ID NO:
- 12 or the complement thereof.
An isolated or purified human polynucleotide consisting of a contiguous span of SEQ ID NO:
- 12 or the complement thereof, wherein said contiguous span includes the biallelic marker at position 67092 of SEQ ID NO:
- 12 and said contiguous span is:
- a) nucleotides 1-70715;
- b) 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500 or 1000 contiguous nucleotides of SEQ ID NO:
- 12;
- c) nucleotides 1-70715 attached to a label or solid support;
- or
- d) 12, 15, 18, 20, 25, 30, 35, 40. 50, 60, 70, 80, 90, 100, 150, 200, 500 or 1000 contiguous nucleotides of SEQ ID NO:
- 12 attached to a label or solid support.
Dependencies are inferred from the claim text.